Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Brugada Syndrome Treatment

Brugada syndrome is characterized by an ST-segment elevation in the right precordial ECG leads and a high incidence of sudden death in patients with structurally normal hearts. Some trials have demonstrated that the cost-effectiveness of ICD implantation treatment in patients with structurally abnormal hearts is more favorable than that of control treatment. We used Treeage pro 2005 to estimate costs and survival among the Brugada syndrome patients who received either an ICD or were treated by control therapy of Ito-blocking properties (quinidine) or β-blockers (propranolol). In conclusion, our analysis suggests that prophylactic implantation of an ICD has good cost-effectiveness in patients with Brugada syndrome who are at high risk of sudden death. ICD treatment has shown a cost-effectiveness ratio below $9,591 per QALY gained from trials of defibrillator vs β-blockers for Unexplained Death in Thailand (DEBUT). The control therapy of quinidine may be a good choice for patients who are infants or living in developing countries.

[1]  A. Khasnis,et al.  Prophylactic Defibrillator Implantation in Patients With Nonischemic Dilated Cardiomyopathy , 2004 .

[2]  Douglas K Owens,et al.  Cost-effectiveness of implantable cardioverter-defibrillators. , 2005, The New England journal of medicine.

[3]  Judy Powell,et al.  Quality of Life in the Antiarrhythmics Versus Implantable Defibrillators Trial: Impact of Therapy and Influence of Adverse Symptoms and Defibrillator Shocks , 2002, Circulation.

[4]  Roger M. Mills.  Clinical Approaches to Tachyarrhythmias, Volume 10: The Brugada Syndrome , 2000 .

[5]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[6]  R. Hauser,et al.  The growing mismatch between patient longevity and the service life of implantable cardioverter-defibrillators. , 2005, Journal of the American College of Cardiology.

[7]  K. Lee,et al.  A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. , 1999, The New England journal of medicine.

[8]  M Gent,et al.  Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. , 2000, Circulation.

[9]  Douglas L Packer,et al.  Effect of Implantable Defibrillators on Arrhythmic Events and Mortality in the Multicenter Unsustained Tachycardia Trial , 2002, Circulation.

[10]  A. Wilde,et al.  Quinidine Induced Electrocardiographic Normalization in Two Patients with Brugada Syndrome , 2001, Pacing and clinical electrophysiology : PACE.

[11]  Louise S Jenkins,et al.  Partner Quality of Life in the Antiarrhythmics Versus Implantable Defibrillators Trial , 2007, The Journal of cardiovascular nursing.

[12]  BernardBelhassen,et al.  Efficacy of Quinidine in High-Risk Patients With Brugada Syndrome , 2004 .

[13]  K. Nademanee,et al.  Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. , 1997, Circulation.

[14]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[15]  S. Viskin,et al.  The Brugada Syndrome: Is an Implantable Cardioverter Defibrillator the Only Therapeutic Option? , 2002, Pacing and clinical electrophysiology : PACE.

[16]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[17]  H Imamura,et al.  Successful Prevention of Recurrent Ventricular Fibrillation by Intravenous Isoproterenol in a Patient with Brugada Syndrome , 2001, Pacing and clinical electrophysiology : PACE.

[18]  R. Klein,et al.  The Beaver Dam Health Outcomes study , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[19]  Wataru Shimizu,et al.  Brugada syndrome: report of the second consensus conference. , 2005, Heart rhythm.

[20]  Stanley P. Azen,et al.  Defibrillator Versus &bgr;-Blockers for Unexplained Death in Thailand (DEBUT): A Randomized Clinical Trial , 2003, Circulation.

[21]  Eric Fain,et al.  Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. , 2004, The New England journal of medicine.

[22]  C Antzelevitch,et al.  The Brugada Syndrome , 1998, Journal of cardiovascular electrophysiology.

[23]  J L Rey,et al.  Prevalence of the brugada syndrome in an apparently healthy population. , 2000, The American journal of cardiology.

[24]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[25]  Wataru Shimizu,et al.  Brugada syndrome: report of the second consensus conference. , 2005, Heart rhythm.

[26]  J. Brugada,et al.  Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. , 1992, Journal of the American College of Cardiology.

[27]  S. Viskin,et al.  Effects of Electrophysiologic‐Guided Therapy with Class IA Antiarrhythmic Drugs on the Long‐Term Outcome of Patients with Idiopathic Ventricular Fibrillation with or without the Brugada Syndrome , 1999, Journal of cardiovascular electrophysiology.

[28]  Antoine Leenhardt,et al.  Hydroquinidine therapy in Brugada syndrome. , 2004, Journal of the American College of Cardiology.

[29]  J. Bigger,et al.  Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. , 1999, Circulation.

[30]  A. Moss,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.

[31]  S Furman,et al.  Automatic implantable cardioverter-defibrillator: patient survival, battery longevity and shock delivery analysis. , 1987, Journal of the American College of Cardiology.

[32]  D Shoshani,et al.  Idiopathic ventricular fibrillation: inducibility and beneficial effects of class I antiarrhythmic agents. , 1987, Circulation.

[33]  K. Kuck,et al.  Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). , 1994, American heart journal.

[34]  J. Brugada,et al.  Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. , 1998, Circulation.

[35]  C Antzelevitch,et al.  Differences in the electrophysiological response of canine ventricular subendocardium and subepicardium to acetylcholine and isoproterenol. A direct effect of acetylcholine in ventricular myocardium. , 1990, Circulation research.

[36]  H Suzuki,et al.  Infant Case with a Malignant Form of Brugada Syndrome , 2000, Journal of cardiovascular electrophysiology.

[37]  T. Iwasaka,et al.  Prevalence and mortality of the Brugada-type electrocardiogram in one city in Japan. , 2001, Journal of the American College of Cardiology.